Drug Candidate 3
Oncology (Likely Lung Cancer)
Undisclosed Preclinical/DiscoveryActive
Key Facts
Indication
Oncology (Likely Lung Cancer)
Phase
Undisclosed Preclinical/Discovery
Status
Active
Company
About Biodesix
Biodesix is a publicly-traded diagnostic company with a mission to transform patient care through timely, personalized diagnostics, primarily in lung cancer. The company has successfully commercialized a suite of blood-based tests, including the FDA-cleared Nodify Lung® and GeneStrat® tests, which are supported by its proprietary AI-driven multi-omics platform and real-world Biodesix Lung Database®. Its strategy is twofold: expanding the clinical adoption of its diagnostic tests while capitalizing on its platform and operational expertise through a growing diagnostic development services business for life sciences partners.
View full company profileTherapeutic Areas
Other Oncology (Likely Lung Cancer) Drugs
| Drug | Company | Phase |
|---|---|---|
| Drug Candidate 1 | Biodesix | Undisclosed Preclinical/Discovery |
| Drug Candidate 2 | Biodesix | Undisclosed Preclinical/Discovery |